HALMAN ALDUBI PROVIDENT AND PENSION FUNDS LTD. v. TEVA PHARMACEUTICAL INDUSTRIES LIMITED et al
Case Number:
2:20-cv-04660
Court:
Nature of Suit:
Other Statutes: Securities/Commodities
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
A shareholder's certified class action against pharmaceutical company Teva can resume after being paused for two years, as the company says it is working towards a settlement with the U.S. Department of Justice over related claims it used kickbacks to raise the price of its multiple sclerosis drug Copaxone, a Philadelphia federal judge has decided.
-
May 16, 2024
3rd Circ. Shuns Teva's 'Novel' Appeal On Israeli Investor Class
The Third Circuit on Thursday turned away an appeal brought by Teva Pharmaceutical Industries Ltd., saying the class certification stage was not the right time to hear arguments over the "novel" question of the applicability of U.S. securities laws to Israeli-listed shares.
-
November 03, 2023
Teva Investors Win Class Cert. In Drug Kickback Suit
A Pennsylvania federal judge on Friday certified a class of Teva Pharmaceuticals investors who claim the company lied about illegal kickback payments it made to cover Medicare copayments of patients taking its multiple sclerosis drug.
-
March 25, 2022
Teva Can't Toss Securities Suit Over Alleged Drug Kickbacks
A Pennsylvania federal judge Friday denied Teva Pharmaceuticals' motion to dismiss a proposed investor class action alleging the company lied about illegal kickback payments it made to cover Medicare copayments of patients taking its multiple sclerosis drug, saying the suit plausibly argues Teva wrongly attributed its success to "legitimate business factors."
-
March 26, 2021
Faruqi & Faruqi To Lead Teva Securities Suit Over Kickbacks
Faruqi & Faruqi LLP was selected Friday to helm a putative investor class alleging that Teva Pharmaceuticals lied about illegal kickback payments it made to charitable foundations to cover Medicare copayments of patients taking its multiple sclerosis drug, according to an order filed in Pennsylvania federal court.